Table 1 Patient characteristics at baseline
From: Phase II trial of nab-paclitaxel in metastatic breast cancer patients with visceral metastases
Characteristics | Total N = 80 | Percentage % |
|---|---|---|
Median Age (range) | 52 (26–86) | |
ER/PR/HER2 status | ||
ER and/or PR positive | 61 | 76.3 |
ER and PR negative | 19 | 23.7 |
HER2 positive | 2 | 2.5 |
HER2 negative | 78 | 97.5 |
Triple negative | 18 | 22.5 |
ECOG | ||
0–1 | 77 | 96.2 |
≥ 2 | 3 | 3.8 |
Menopausal status | ||
Premenopausal | 22 | 27.5 |
Postmenopausal | 58 | 72.5 |
Metastatic sites | ||
Lung | 49 | 61.3 |
Liver | 54 | 67.5 |
Brain | 5 | 6.3 |
Number of metastatic sites | ||
1–2 | 30 | 37.5 |
≥ 3 | 50 | 62.5 |
Prior metastatic chemotherapy regimens | Median: 2 (Range 0–8) | |
0 | 30 | 37.5 |
1 | 22 | 27.5 |
≥ 2 | 28 | 35 |
Combined Treatment | ||
Yes | 12 | 15 |
No | 68 | 85 |